Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2

Citation
Stivaros, S. M., A. O. Stemmer-Rachamimov, R. Alston, S. R. Plotkin, J. B. Nadol, A. Quesnel, J. O'Malley, et al. 2015. "Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2." Journal of Medical Genetics 52 (8): 557-562. doi:10.1136/jmedgenet-2015-103050. http://dx.doi.org/10.1136/jmedgenet-2015-103050.

Published Version
doi:10.1136/jmedgenet-2015-103050

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:21462664

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
ORIGINAL ARTICLE

Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2

Stavros M Stivaros,1,2,3 Anat O Stemmer-Rachamimov,4 Robert Alston,5 Scott R Plotkin,6 Joseph B Nadol,7 Alicia Quesnel,7 Jennifer O’Malley,7 Gillian A Whitfield,8 Martin G McCabe,9 Simon R Freeman,10 Simon K Lloyd,10 Neville B Wright,1 John-Paul Kilday,3 Ian D Kamaly-Asl,3,11 Samantha J Mills,12 Scott A Rutherford,13 Andrew T King,13 D Gareth Evans14

ABSTRACT

Background Neurofibromatosis Type 2 (NF2) is a dominantly inherited tumour syndrome with a phenotype which includes bilateral vestibular (eighth cranial nerve) schwannomas. Conventional thinking suggests that these tumours originate at a single point along the superior division of the eighth nerve.

Methods High resolution MRI was performed in children genetically proven to have NF2. The superior vestibular nerve (SVN) and inferior vestibular nerve (IVN) were visualised along their course with points of tumour origin calculated as a percentage relative to the length of the nerve.

Results Out of 41 patients assessed, 7 patients had no identifiable eighth cranial nerve disease. In 16 patients there was complete filling of the internal auditory meatus by a tumour mass such that its specific neural origin could not be determined. In the remaining 18 cases, 86 discrete separate foci of tumour origin on the SVN or IVN could be identified including 23 tumours on the right SVN, 26 tumours on the right IVN, 18 tumours on the left SVN and 19 tumours on the left IVN.

Discussion This study, examining the origins of vestibular schwannomas in NF2, refutes their origin as being from a single site on the transition zone of the superior division of the vestibular nerve. We hypothesise a relationship between the number of tumour foci, tumour biology and aggressiveness of disease. The development of targeted drug therapies in addition to bevacizumab are therefore essential to improve prognosis and quality of life in patients with NF2 given the shortcomings of surgery and radiation treatments when dealing with the multifocality of the disease.

BACKGROUND

Neurofibromatosis Type 2 (NF2) is a dominantly inherited tumour syndrome affecting approximately 1 in 33 000 live births.1 It has a neuroradiological phenotype characterised by the development of tumours of the central and peripheral nervous system including schwannomas, meningiomas and ependymomas.2,3 While schwannomas can be present on any of the cranial nerves (except the optic), the classic finding in NF2 is of bilateral vestibular (eighth cranial nerve) schwannomas (VS). As such, the radiological finding of bilateral VS is the main diagnostic criterion for NF2,3,4 although the reason for the predilection for the vestibular nerve remains unexplained.

The imaging of VS has been the subject of progressive scrutiny especially given the recent development of anti-angiogenic treatments such as the antivascular endothelial growth factor A antibody bevacizumab.5 Overall tumour size can be an important factor with regards to tumour assessment while on therapy and when determining a patient’s eligibility for treatment. Recent work has demonstrated that simple linear measurement of these tumours is not a parameter for satisfactory assessment given their morphological appearance extending out of the internal auditory meatus (IAM) with an associated large cerebellopontine angle (CPA) component (figure 1). Consequently, a volumetric assessment of VS has been shown to be more accurate in determining their size and growth rate.6

The anatomical measurement of these vestibular tumours is complicated by their morphology. For instance, in the CPA their configuration is as a multilobulated mass of tumour surrounding the facial and cochlear nerves.7 Furthermore, there are typically two components to these tumours; one filling and bounded by the bony margins of the IAM itself and the second manifesting as a continuation into an adjoining CPA component (figure 1).

This morphology has often been discussed with regards to its nature and origin. Conventional thinking has for many years been that the tumours originate as solitary lesions at a point along the eighth cranial nerve called the junctional zone or glial–schwann cell junction, primarily thought to be on the superior division of the nerve.7,8 Given the advances in high resolution vestibular nerve volumetric imaging, it is now feasible to assess more accurately the eighth cranial nerve in vivo and thereby validate these preceding hypotheses on vestibular schwannoma origin. As a national referral centre for children with NF2, we are able to perform standardised high-resolution imaging at an early time point in the disease process on a large cohort of children genetically proven to have NF2. Using this technique, we present the first report on the specific neural site of origin of these tumours and their relation to the vestibular nerve as a whole.

METHODS

Study design and patient selection

This study was subject to local ethical review. Within the UK, the National Health Service has
commissioned national groups to centralise the investigation, diagnosis, management and treatment of rare but significant disease processes. Neurofibromatosis Type 2 is such a commissioned service. The North of England and Scotland are served by the Manchester Unit, based in the Clinical Genetics Department at St Mary’s Hospital, Manchester, UK. Paediatric patients are managed at the adjoining Royal Manchester Children’s Hospital, one of the largest dedicated children’s hospitals in Europe. All the imaging assessed in this study was acquired as part of this clinical management process.

MRI acquisition and assessment
As part of the imaging assessment, all children referred to the NF2 service had dedicated MRI assessment of the brain and spine performed on a 1.5-tesla Avanto scanner (Siemens Healthcare, Erlangen Germany) using a dedicated head coil. Given the age range of our patient cohort, the methods for facilitating imaging vary, being determined by the clinical referral team in conjunction with radiology. Where sedation was necessary this followed routine protocol using chloral hydrate at 100 mg/kg child weight up to a maximum of 2 g dose. If necessary, patients were also referred for play therapy to facilitate successful imaging. All imaging was performed following the intravenous administration of a gadolinium-based contrast medium (Dotarem, Guerbet USA) at a dose of 0.2 ml/kg child weight which equates to 0.1 mmol/kg.

Specific to this study, three pulse sequences were employed: Coronal T1 weighted volume whole brain gradient echo sequence, TR 1160, TE 4.44, slice thickness 1 mm, field of view 230 matrix 192x256 with an acquisition time of 3 min 44 s. Axial and coronal whole brain spin echo T1 sequences with fat saturation, TR 556, TE 17, 3 mm slice thickness, field of view 220, matrix size 162x256 with an acquisition time of 6 min 55 s each.

Each MRI scan was reviewed by the same dedicated paediatric neuroradiologist. In cases where a finding was not definitive, confirmation was obtained from a second paediatric radiologist with an interest in neuroradiology. All imaging reviews were performed on a General Electric RA 1000 PACS workstation (GE Healthcare, USA).

Image grading
The T1 axial and coronal fat saturated images were used to give a general overview of any identifiable vestibular schwannoma. A measurement was made of the eighth cranial nerve along its course from the brainstem to the fundus of the IAM using the reformats to guide this measurement by tracing the course of the nerve in all three orthogonal planes. Measurement was made along the nerve to ascertain the length of the nerve from the point of its transition through the porus acusticus into the IAM and along to its termination at the fundus of the IAM. Points were then plotted along the nerves at the sites of tumour origin identified by foci of contrast enhancement (figure 2).

The position of the foci of tumour enhancement was then calculated as a percentage relative to the length of the nerve from the porus acusticus to the fundus of the IAM with a position at the porus being defined as 0% along the nerve length and a position at the fundus being 100% along the nerve.

Statistical methods
The relationship between the number of tumours on the left and right sides of the head and between the IVN and SVN was assessed using Fisher’s exact test on the tabulated data. The significance of the relative positions of tumours along the nerve was assessed using a Kolmogorov–Smirnov test for a uniform distribution in the relative position. p Values of less than 0.05 were considered significant and analyses were performed using R (The R Foundation for Statistical Computing, Vienna, Austria).

RESULTS
Patient cohort characteristics
In total, 41 patients with genetically proven NF2 were assessed as part of the study: 59% boys and 41% girls. The mean age was 10.6 years (range: 1.0–19.0). Within the study sample, seven patients were found to have no identifiable vestibular nerve disease leaving 34 patients with measurable disease. The mean age of the disease-positive group was 11.4 years (range: 1.0–19.0).

Laterality and discernibility of site of tumour origin
In patients where tumours were identified, only two patients presented with unilateral disease. In one patient there was a single point of tumour origin (with no disease seen on the opposite side) and in the second patient there was complete filling of the IAM with no disease seen on the opposite side. In all the other patients, bilateral disease was seen. The number of tumours and their laterality is shown in table 1.

---

**Figure 1** T1 spin echo sequences (axial—A and coronal—B), both with fat saturation and contrast administration showing the typical imaging phenotype of a patient with neurofibromatosis Type 2. There are bilateral vestibular schwannomas that have a component within the internal auditory meatus (dashed arrow) as well as within the cerebellopontine angle (CPA, solid arrows). These components are in continuity and thought to represent one tumour mass. Further discrete disease is seen in the right vestibule (dotted arrow). The coronal sequence again shows the bilateral CPA angle components of the tumours compressing the brainstem (white arrows).
Number of tumours and location

In 18 patients, the point of origin of the tumours could be localised to a specific site on the vestibulocochlear nerve in the CPA, or on the SVN or IVN in the IAM, and a total of 86 tumour foci were identified. In no cases did the tumour location comply with the conventional hypothesis of a single tumour focus on the superior division of the vestibular nerve alone.

In total, 23 tumours were seen on the right SVN in 17 patients with 26 tumours identified on the right IVN in 16 patients. In one case, the whole of the right IVN was seen to discretely enhance. In total, 18 tumours were found to originate from the left SVN in 12 patients with the left IVN being the site of tumour origin for 19 tumours in 8 patients. In addition there were two cases where both the left SVN and IVN were seen to enhance along their whole course. It was not possible to determine if these cases were true tumour foci or schwannomatosis. For this reason they were excluded from this analysis. In two cases (one on each side), a tumour was seen medial to the porus acusticus on the vestibulocochlear nerve within the CPA.

Figure 3 shows the cumulative distribution of the positions of identified tumours along the SVN and IVN.

The relative position of the tumours on the SVN and IVN was calculated as (tumour position – porus position)/(total length – porus position). The two tumours before the porus were ignored. A Kolmogorov–Smirnov test was significant for the superior nerve tumours (p<0.001) but not for the inferior nerve tumours (p=0.11), both as two-sided tests which indicates a statistical predominance for a tumour position towards the fundus of the IAM on the SVN. The inferior nerve tumours were not displaced as far, although the positional difference between them and the superior nerve tumours (two sample Kolmogorov–Smirnov test) was not significant (p=0.55).

**DISCUSSION**

The radiological assessment of a child presenting with sensorineural hearing loss or clinical features of NF2 mandates early high-resolution imaging of the inner ear structures using MRI. This is usually in the form of a heavily T2 weighted axial acquisition (figure 2C). However, in the NF2 cohort a comprehensive

### Table 1

Tabulated data showing the number of tumours identified on both the superior and inferior vestibular nerves for each patient

| Number of tumours | Left | Total |
|-------------------|------|-------|
|                   | None | 1     | 2     | 3–5  | Full | Total |
| Right             |      |       |       |      |      |       |
| None              | 7    | 0     | 0     | 4    | 0    | 11    |
| 1                 | 1    | 0     | 1     | 1    | 0    | 3     |
| 2                 | 0    | 0     | 3     | 1    | 0    | 4     |
| 3–5               | 0    | 2     | 0     | 5    | 1    | 8     |
| Full              | 1    | 0     | 1     | 0    | 13   | 15    |
| Total             | 9    | 2     | 5     | 11   | 14   | 41    |

*Full* implies the tumour mass could not be identified as a single tumour focus of origin and was filling the internal auditory meatus, with or without cerebellopontine angle encroachment. Fisher’s exact test for independence of the numbers of left and right hand tumours is significant at p<0.001.
assessment must include high-resolution post-contrast imaging as the evidence presented here clearly demonstrates foci of tumour enhancement along the components of the eighth nerves before discrete masses are demonstrated (figure 2). Some published works on sporadic eighth nerve schwannomas have demonstrated that there is no evidence for the commonly held belief that the tumour originates in the junctional zone, and in addition, resection specimens have shown an increased incidence of sporadic tumour in the inferior branch (84.8%) compared with the superior branch (8.9%) of the vestibular nerve based on 269 sporadic cases. This study demonstrates that in the NF2 cohort there is no predilection for tumour origin in either the superior or inferior branches of the vestibular nerves in NF2 with both branches being affected equally. This study demonstrates that in addition to the bilaterality of vestibulocochlear disease in NF2, what can appear as a single tumour once established in fact comprises more than one focus of tumour originating at multiple sites on the SVN and IVN from the very earliest stages. In addition, contrary to the commonly held belief that the site of origin of VS is at the junctional zone, this study also shows that there is no specific site along the nerves within the IAM that has an increased incidence of tumour origin. There is a statistically significant finding that the sites of origin are more lateral on the SVN.

In sporadic VS, the lesion is generally a single tumour arising from the vestibular nerve at the porus acusticus. The adjacent facial and cochlear nerves are external to the tumour and displaced by it. We hypothesise that in VS these multiple sites of origin of VS go some way to explaining the difference in phenotypical description of a multilobulated tumour that appears like a ‘bunch of grapes’. In NF2, as the tumours grow they eventually coalesce into one tumour mass. However, they retain their origin along the nerve such that the tumour bulk comprises an amalgamation of multiple tumour foci which envelope the facial and cochlear nerves. This explains the difference in the radiological phenotype seen as first postulated by Martuza and Ojemann. This is also likely to explain the lobulated pattern with the nerve fibres embedded in the tumour as shown histologically. We also suggest that there is a correlation between the multiplicity of tumour origin and the aggressiveness of the overall NF2 disease process on an individual patient basis.

We have also reported a separate tumour site involvement of the cochlear nerve and within the vestibule alongside multiple foci on the SVN and IVN, a finding that has significant clinical importance as it suggests that hearing and balance impairment could be related to separate involvement at these anatomical sites and not necessarily simply related to tumour size or growth along the tumour itself as currently thought. This is correlated by histopathological work in NF2 cohorts of patients referred for temporal bone resection. Histological studies of these resections confirm multicentricity of tumour foci on the eighth cranial nerve in 19/26 cases (73%) from 16 NF2 patients where multiple, separate, discrete tumour nodules were
identified within the internal auditory canal (IAC) as well as within the labyrinth. Multiple tumour nodules were observed in the labyrinth involving the cochlea, vestibule or semicircular canals. The intralabyrinthine tumours were not a result of IAC tumour invasion which is therefore supportive of the imaging hypothesis of a multifocal tumour origin (figure 4).14

Furthermore, in a recent NF2 genetically engineered mouse model, generated through excision of the NF2 gene driven by Cre expression (restricted to periostrin promoter element), the NF2 mice developed multiple schwannomas in peripheral and cranial nerves. Interestingly, as per this study, multiple, separate tumour nodules were present within the eighth cranial nerve, with multifocal origin of schwannomas identified in this mouse model.16

Outcomes from vestibular schwannoma microsurgery have long been shown to be inferior in patients with NF2 when compared with those from sporadic cases.6 17–19 The higher tumour recurrence rates observed with both hearing preservation surgery and the trans-labyrinthine approach which more reliably removes all tumour suggest that a large proportion of these recurrences may be new primary tumours or tiny tumourlets that were not visible to the surgeon at the time of surgery.17 18 The 59% recurrence rate in children who have undergone middle fossa cochlear nerve preserving surgery argues against this practice as a means of long-term hearing preservation even if both vestibular nerves are resected at the time of original surgery as does the presence of both facial and cochlear nerve schwannomas in temporal bone dissections.14 17 20

Several case series also suggest inferior rates of local control for NF2 as compared with sporadic VS after radiosurgery,19 21 22 although others have shown excellent results.23 Reasons for radioresistance of VS are poorly understood.24 If radiosurgery was undertaken for a very small NF2 vestibular schwannoma which had not yet reached the fundus of the IAM or the porus acusticus, then this article argues that careful consideration should be given to the treatment volume taking into account the possibility of multifocal lesions at the margins of the tumour, not identified on imaging, that may be receiving sub-therapeutic doses.

As discussed above, a radiological phenotype of bilateral IAM schwannomas relating to the eighth cranial nerves is pathognomonic of an underlying diagnosis of NF2 rather than the presence of a sporadic eighth nerve schwannoma.5 Additionally, we now suggest that the presence of an apparently isolated multifocal vestibular schwannoma should raise the strong possibility that the individual has a form of NF2.

In summary, this study refutes the origin of vestibular tumours in NF2 as simply being on the SVN, originating as a single tumour at the transition zone along that nerve. We also believe that it explains the later morphological appearance of these tumours in the older age group.

It is also hypothesised that there may be a relationship between the number of tumour foci and the aggressiveness of the disease process, as well as the likelihood of involvement of the facial and cochlear nerves. However, prospective longitudinal data obtained by a follow-up of the clinical outcomes in this cohort is necessary to illuminate this. Further work is also required to investigate whether underlying biological differences account for variation in both the number and location of vestibular schwannoma tumour foci seen within this NF2 patient cohort. It is largely conceivable that such differences would go some way to explaining why some of these children seem to respond to bevacizumab while others do not.

It remains apparent however that the development of targeted drug therapies such as bevacizumab are essential to improve quality of life and life expectancy in patients with NF2, particularly given the shortcomings of surgery and radiation treatments to deal with the multifocality of disease.

Author affiliations
1Academic Unit of Paediatric Radiology, Royal Manchester Children’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester
2Academic Health Science Centre, Manchester, UK
3Centre for Imaging Sciences, Institute of Population Health, University of Manchester, Manchester, UK
4Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
5National Drug Evidence Centre (NDEC), Centre for Epidemiology, Institute of Population Health, University of Manchester, Manchester, UK
6Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
7Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA
8Radiotherapy Related Research, The Christie NHS Foundation Trust, Manchester, UK
9Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, University of Manchester, Manchester, UK
10Department of Otolaryngology, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
Cancer genetics

1Department of Paediatric Neurosurgery, Royal Manchester Children’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
2Department of Neuroradiology, Salford NHS Foundation Trust Hospital, Salford, Greater Manchester, UK.
3Department of Neurosurgery, Salford Royal Hospital, Salford, Greater Manchester, UK.
4Department of Genomic Medicine, St. Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Contributors Study coordination was conducted by SMS and DGE. Clinical assessment: SRP, JBN, GAW, MGM, SRF, SKL, JPK, IDK-A, SAR, ATK and DGE. Image assessment: SMS, NBW and SJM. Temporal bone specimen analysis: AOS-R, JBN, AQ and JC’M. Statistical analysis and verification: RA, SMS and GAW. All authors have been involved in the drafting, critical revision and final approval of the manuscript for publication and agree to be accountable for all aspects of the accuracy and integrity of the work.

Funding National Institute for Health Research (NIHR) and facilitated by the University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

Competing interests None declared.

Ethics approval Local Research Approval and Caldicott Guardian Approval. Research Network. SMS funded by NIHR under award number NIHR/CS/010/021.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES
1. Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Laloo F. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A:327.
2. Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neoplasms). N Engl J Med. 1988;318:684–8.
3. Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009;4:16.
4. Lloyd SKW, Evans DGR. Neurofibromatosis type 2 (NF2): diagnosis and management. In: Koke H, Sobue G, eds Handbook of clinical neurology. Vol 115. Amsterdam, NL: Elsevier, 2013:957–67.
5. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG II. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33:1046–52.
6. Harris GJ, Plotkin SR, MacCollin M, Bhat S, Urban T, Lee MH, Slattery WH. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 2008;62:1314–19.
7. Martuza RL, Ojemann RG. Bilateral acoustic neoplasms: Clinical aspects, pathogenesis and treatment. Neurosurgery. 1982;10:1–12.
8. Neely JG. Gross and microscopic anatomy of the eighth cranial nerve in relationship to the solitary schwannoma. Laryngoscope. 1981:91:1512–31.
9. Wu C-L, Neary W, Thakker N, Black G, Lye R, Read A, Ramsden RT, Evans DGR. Differential diagnosis of type 2 neurofibromatosis: molecular discrimination of NF2 and sporadic vestibular schwannomas. J Med Genet. 1998;35:973–7.
10. Roosli C, Linthicum FH Jr, Cureoglu S, Merchant SN. What is the site of origin of cochleovestibular schwannomas? Audiol Neurootol. 2012;17:121–5.
11. Xenellis JE, Linthicum FH Jr. On the myth of the giall/swann junction (Obersteiner-Redlich zone): origin of vestibular nerve schwannomas. Otol Neurotol. 2009;30:41.

12. Department of Genomic Medicine, St. Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.

13. Clemis JD, Ballad WJ, Baggot PJ, Lyon ST. Relative frequency of inferior vestibular schwannoma. Arch Otalaryngol Head Neck Surg. 1986;112:190–40.

14. Nam S, Linthicum FH Jr, Merchant SN. Temporal bone histopathology in neurofibromatosis type 2. Laryngoscope 2011;112:1546–54.

15. Sobel RA, Wang Y. Vestibular (Acoustic) Schwannomas: histological features in neurofibromatosis 2 and unilateral cases. J Neurolab N Eur Neurol. 1993:52:106–13.

16. Gehlhauer JR, Park SJ, Hickox AE, Shew M, Staser K, Rhodes SD, Menon K, Lajiness JD, Mwanthi M, Yang X, Yuan J, Ternito P, Hutchins G, Nalepa G, Yang FC, Conway SI, Heinz MG, Stummer-Rachamimov A, Yates CW, Wade Clapp D. A murine model of Neurofibromatosis Type 2 that accurately phenocopies human schwanna formation. Hum Mol Genet. 2015;1:1–8.

17. Friedman RA, Goddard JC, Wilkinson EP, Schwartz MS, Slattery WH III, Fayad JN, Brackmann DE. Hearing preservation with the middle cranial fossa approach for neurofibromatosis type 2. Otol Neurotol. 2011;32:1530–7.

18. Moffat DA, Lloyd SK, Maclaraine R, Mannion R, King A, Rutherford S, Axon PR, Donnelly N, Freeman S, Tysome JR, Evans DG, Ramsden RT. Outcome of translabyrinthine surgery for vestibular schwannoma in neurofibromatosis type 2. Br J Neurosurg. 2013;27:446–53.

19. Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry. 2003;74:1288–93.

20. MacNally SP, Rutherford SA, King AT, Freeman S, Tysome JR, Evans DG, Ramsden RT. Outcome from surgery for vestibular schwannomas in children. Br J Neurosurg. 2009;23:226–31.

21. Sharma MS, Singh R, Kale SS, Agrawal D, Sharma BS, Mahapatra AK. Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2. J Neurooncol. 2010;98:265–70.

22. Phi JH, Kim DG, Chung HT, Lee J, Peek SH, Jung HW. Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation. Cancer. 2009;115:390–8.

23. Subach BR, Kondziolka D, Lunsford LD, Bissonnette DJ, Flickinger JC, Maitz AH. Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis Type 2. J Neurol Neurosurg Psychiatry. 1999;30:815–22.

24. Yeung AH, Sughrue ME, Kane AJ, Tihan T, Cheung SW, Parsa AT. Radiobiology of vestibular schwannomas: mechanisms of radioresistance and potential targets for therapeutic sensitization. Neurosurg Focus. 2009;27:E2.

562 Stivaros SM, et al. J Med Genet 2015;52:557–562. doi:10.1136/jmedgenet-2015-103050